Robust preclinical model of Neurodegeneration: The MPTP-Induced Parkinsonism

Context and Rationale

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta and subsequent depletion of striatal dopamine. To study the mechanisms underlying dopaminergic neurodegeneration and to assess therapeutic interventions, robust and reproducible preclinical models are essential.

The MPTP-induced Parkinsonism model replicates key pathological and behavioural features of PD. MPTP readily crosses the blood–brain barrier and is converted by astrocytic monoamine oxidase-B (MAO-B) into 1-methyl-4-phenylpyridinium (MPP^+), which selectively targets dopaminergic neurons, leading to mitochondrial dysfunction and neuronal loss. The resulting motor impairments closely resemble those observed in human Parkinson's disease. This model is widely employed to investigate the pathogenesis of Parkinson's disease and to evaluate potential therapeutic interventions.

Experimental Framework

© 2026 TCG Lifesciences – Confidential & Proprietary

Model Description

Parameter	Description
Animal Species	Male C57BL/6 mice
Induction	Two doses of MPTP administered intraperitoneally at 16-hour intervals
Endpoints	Striatal dopamine level, akinesia duration, catalepsy duration, rotarod test performance

MPTP administration (two intraperitoneal doses given 16 hours apart) resulted in approximately a threefold reduction in striatal dopamine levels. This biochemical depletion was accompanied by behavioural impairments, including prolonged akinesia, catalepsy, and a marked decline in rotarod performance, collectively confirming the induction of parkinsonian symptoms.

Observations and Analysis





© 2026 TCG Lifesciences – Confidential & Proprietary

- MPTP administration (2 doses; IP at 16 hr interval) reduced striatal dopamine level by about threefold, which was also well reflected in noticeable behavioural impairments in terms of prolonged akinesia & catalepsy as well as marked decline in rotarod performance.

- Deprenyl treatment (1 mg/kg, IP, BID for 6 days) could not reverse the MPTP-induced dopamine depletion at all and thereby could not improve any behavioural impairment. Although improvement of behavioural impairment by DEP is reported in some literatures, the reversal effect in correlation with dopamine levels is not clearly depicted for DEP. In our study, probably pronounced dopaminergic neuronal loss by MPTP led to significant reduction in striatal dopamine levels which could not be reversed by DEP.

Translational Implications

The MPTP-induced Parkinsonism model remains a useful tool for studying dopaminergic neurodegeneration and testing neuroprotective agents. By producing quantifiable biochemical and behavioural endpoints, the model offers a translational link between cellular pathology and motor dysfunction in Parkinson's disease.

Its reproducibility, defined pharmacological response, and mechanistic alignment with human PD make it a useful tool for evaluating disease-modifying compounds and exploring the progression of neurodegenerative processes.

Property of TCGLS